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Pneumonectomy for malignant disease is associatedwith significant morbidity and mortality.1,2 Little infor-
mation, however, is known regarding predisposing fac-
tors. The purpose of this review was to evaluate our results
in patients undergoing pneumonectomy for cancer.
Patients and methods
Between January 1, 1985, and September 30, 1998, 639
patients underwent elective pneumonectomy for malignancy
Objective: The purpose of this report is to analyze factors affecting morbidi-
ty and mortality after pneumonectomy for malignant disease.
Methods: We retrospectively reviewed the cases of all patients who under-
went pneumonectomy for malignancy at the Mayo Clinic. Between January
1, 1985, and September 30, 1998, 639 patients (469 men and 170 women)
were identified. Median age was 64 years (range 20 to 86 years). Indication
for pneumonectomy was primary lung cancer in 607 (95.0%) patients and
metastatic disease in 32 (5.0%). Factors affecting morbidity and mortality
were analyzed by univariate and multivariate analysis.
Results: Cardiopulmonary complications occurred in 245 patients (38.3%;
95% confidence interval 34.6%-42.2%). Factors adversely affecting mor-
bidity with univariate analysis included age (P < .0001), male sex (P = .04),
associated respiratory (P = .02) or cardiovascular disease (P < .0001), cig-
arette smoking (P = .02), decreased vital capacity (P = .01), forced expira-
tory volume in 1 second (P < .0001), forced vital capacity (P = .002), dif-
fusion capacity of the lung to carbon monoxide (P = .005), oxygen
saturation (P < .05), arterial PO2 (P = .007), preoperative radiation (P = .02),
bronchial stump reinforcement (P = .007), crystalloid infusion (P = .01),
and blood transfusion (P = .02). Factors adversely affecting morbidity with
multivariate analysis included age (P = .0001), associated cardiovascular
disease (P = .001), and bronchial stump reinforcement (P = .0005). There
were 45 deaths (7.0%; 95% confidence intervals 5.2%-9.3%). Factors
adversely affecting mortality with univariate analysis included associated
cardiovascular (P < .0001) or hematologic disease (P < .005), lower preop-
erative serum hemoglobin level (P = .004), preoperative chemotherapy 
(P = .01), decreased diffusion capacity of lung to carbon monoxide 
(P = .002), right pneumonectomy (P = .0006), extended resection (P = .04),
bronchial stump reinforcement (P = .007), and crystalloid infusion 
(P = .01). Factors affecting mortality with multivariate analysis included
hematologic disease (P = .01), lower preoperative serum hemoglobin 
(P = .003), and completion pneumonectomy (P = .01).
Conclusion: Multiple factors adversely affected morbidity and mortality after
pneumonectomy for malignant disease. Appropriate selection and meticu-
lous perioperative care are paramount to minimize risks in those patients
who require pneumonectomy. (J Thorac Cardiovasc Surg 2001;121:1076-82)
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at the Mayo Clinic in Rochester, Minnesota. The records of
these patients were analyzed for age, sex, preoperative condi-
tions, pulmonary function and gas exchange tests, indications
for operation, preoperative clinical stage, adjuvant treatment,
extent of operation, morbidity, and operative mortality.
Morbidity included all complications occurring during hospi-
talization only. Postoperative respiratory failure was consid-
ered to be present if any of the following criteria were pres-
ent: mechanical ventilatory support greater than 24 hours,
positive airway pressure mask required at any time, or sup-
plemental oxygen required after hospital dismissal. Retained
secretions were considered to be present when bronchoscopy
was necessary for removal. Mortality (operative deaths)
included both those patients who died within the first 30 days
after the operation and those who died later but during the
same hospitalization. 
The primary end points of analysis were morbidity and
mortality. The effects of risk factors on these end points were
evaluated with both univariate and multivariate analysis. Risk
factors represented by continuous variables were assessed by
use of 2-sample t tests3 when the data were approximately
normal and by rank sum tests4 when the data were found to
be not sufficiently gaussian. The effects of categorical vari-
able risk factors were evaluated by means of χ2 tests5 and the
Fisher exact tests.6 Multiple logistic regression7 was used
during multivariate analysis to simultaneously evaluate the
effects of risk factors. Specifically, stepwise selection was
used to identify significant predictors. Variables found to be
significant in the logistic regression models were reported by
means of odds ratios with 95% confidence intervals (CI). All
statistical tests were 2-sided. All analyses were conducted
with the SAS statistical program (SAS Institute Inc, Cary,
NC).
Clinical findings. A total of 639 patients (469 men and 170
women) were evaluated. Median age was 64 years and ranged
from 20 to 86 years. Indication for pneumonectomy was pri-
mary lung cancer in 607 (95.0%) patients and metastatic can-
cer in 32 (5.0%). Primary lung cancers were classified as
stage IA in 51 patients, IB in 72, IIA in 135, IIB in 6, IIIA in
302, and stage IIIB in 41. Cell type included squamous cell
carcinoma in 354 patients, adenocarcinoma in 169, large cell
undifferentiated in 44, bronchoalveolar in 16, carcinoid in 11,
and other in 13. The site of origin of metastatic disease was a
soft tissue sarcoma in 13 patients, osteogenic sarcoma in 5,
melanoma in 3, lymphoma in 3, breast carcinoma in 2, and
other in 6. 
Associated conditions were present in 305 (47.7%) patients
and included chronic obstructive pulmonary disease in 183
(28.6%) (Table I), coronary artery disease in 84 (13.1%), car-
diac arrhythmia in 58 (9.1%), diabetes mellitus in 54 (8.5%),
alcoholism in 38 (5.9%), asthma in 29 (4.5%), valvular heart
disease in 25 (3.9%), corticosteroid use in 25 (3.9%), con-
gestive heart failure in 11 (1.7%), hematologic disease in 11
(1.7%), chronic renal failure in 5 (0.1%), and other in 71
(11.1%). The median serum hemoglobin value was 13.4 g/dL
(range 7.4-17.5 g/dL). 
Seventy-five (11.7%) patients had a history of nonpul-
monary malignancy. A total of 578 (90.5%) patients were
chronic cigarette smokers (median 50 pack-years; range 7-96
pack-years), and 186 (29.1%) of these patients were smoking
in the 8 weeks preceding pneumonectomy. Eighteen patients
(2.8%) lost a median of 8.2 kg (range 1.8-27.3 kg) before
pneumonectomy. Median body mass index was 25.9 kg/m2
(range 15.9-60.4 kg/m2).
Sixty-two patients (9.7%) had a prior lung resection; 57
had 1 previous resection, 3 had 2 resections, and 2 had 3
resections. Previous pulmonary resections included lobecto-
my in 37 patients, wedge or segmentectomy in 29, and
bilobectomy in 3. Sixty-three (9.9%) patients had preopera-
Table I.  Preoperative pulmonary function values 
in 639 patients undergoing pneumonectomy
Variable Median (range) No. of patients
TLC (% predicted) 98 (45-152) 348
VC (% predicted) 88 (36-151) 486
FVC (% predicted) 84 (4-151) 529
FEV1 (% predicted) 73 (27-152) 543
RV (% predicted) 111 (52-258) 348
DLCO, exercise (% predicted) 76 (26-99) 388
O2 saturation, rest (%) 95 (82-100) 356
O2 saturation, exercise (%) 93 (80-99) 345
PaO2 (mm Hg) 75 (50-100) 79
PaCO2 (mm Hg) 37 (31-54) 79
TLC, Total lung capacity; VC, vital capacity; FVC, forced vital capacity;
FEV1, forced expiratory volume in 1 second; RV, residual volume; DLCO, dif-
fusion capacity of lung to carbon monoxide; O2, oxygen; PaO2, arterial partial
pressure of oxygen; PaCO2, arterial partial pressure of carbon dioxide.
Table II. Complications in 276 (43.2%) of the 639
patients undergoing pneumonectomy
Complications No. (%)
Respiratory 260 (40.7)
Respiratory failure 102 (16.0)
Retention of secretions 86 (13.5)
Pneumonia 65 (10.2)
PPPE 7 (1.1)
Cardiovascular 190 (29.7)
Arrhythmia 167 (26.1)
Atrial fibrillation 137 (21.4) 
Supraventricular tachycardia 28 (4.4)
Ventricular 7 (1.1)
Congestive/right heart failure 19 (3.0) 
Acute myocardial infarction 4 (0.6)
Empyema 36 (5.6)
Bronchopleural fistula 25 (3.9)
Hemothorax 10 (1.6)
Wound infection 9 (1.4)
Pulmonary embolus 7 (1.1)
Cerebrovascular accident 6 (1.0)
Chylothorax 2 (0.3)
Esophagopleural fistula 2 (0.3)
Other 37 (5.8)
PPPE, Postpneumonectomy pulmonary edema.
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tive adjuvant therapy, including chemotherapy within 3
months of pneumonectomy in 21, radiation in 18, and a com-
bination of both in 24. Two hundred eighty-five (44.6%)
patients had mediastinoscopy before pneumonectomy. 
Pneumonectomy was on the left in 333 (52.1%) patients
and on the right in 306 (47.9%). An extended resection was
performed in 290 (45.4%) patients, including intrapericardial
dissection in 213 (33.3%), en bloc parietal pleura resection in
77 (12.1%), en bloc chest wall resection in 67 (10.5%), a por-
tion of left atrium in 20 (3.1%), carinal resection in 20
(3.1%), diaphragm in 12 (1.9%), superior vena cava in 12
(1.9%), esophageal muscle in 8 (1.3%), thoracic aortic
adventitia in 6 (1.0%), and right atrium, vertebral fascia,
spine, and main pulmonary artery in 1 (0.2%) each.
Extracorporeal circulation was used in 2 (0.3%) patients.
Completion pneumonectomy was performed in 57 (8.8%)
patients. A complete mediastinal lymph node dissection was
performed in 618 (9.0%) patients. The bronchus was closed
with a stapling device in 588 (92.0%) patients and hand-
sutured in 51 (8.0%). The bronchial stump was reinforced in
117 (18.3%) patients and included muscle in 59, parietal
pleura in 40, and pericardium in 18. The serratus anterior
muscle was used to reinforce the bronchial stump in 45
patients, latissimus dorsi in 12, and a combination of both in
2. Tube thoracostomy was used to balance the mediastinum
in 628 patients. The chest tube was removed immediately
after pneumonectomy in 499 patients, during the first postop-
erative day in 122, the second postoperative day in 5, and the
third postoperative day in 2. 
Eighty-six (13.5%) patients had at least one intraoperative
blood transfusion (median 2 units, range 1-37 units), and 33
(5.2%) had at least one transfusion within the first 24 postop-
erative hours (median 2 units, range 1-18 units). Overall, 100
patients had at least one blood transfusion (median 2 units,
range 1-39 units). Median volume of crystalloid solution
infused in the first 12 hours, including intraoperatively, was
19.9 mL/kg (range 0.96-201.1 mL/kg). Median volume of
crystalloid solution infused in the first 24 hours, including
intraoperatively, was 28.2 mL/kg (range 3.1-109.8 mL/kg).
Results
Complications occurred in 276 (43.2%) patients
(Table II). There were 45 deaths (mortality 7.0%; 95%
CI 5.2%-9.3%). Mortality was 6.9% (n = 42) for
patients with primary lung cancer and 9.4% (n = 3) for
patients with metastatic cancer. Thirty-seven deaths
occurred during hospitalization and 8 after hospital dis-
missal. One (0.2%) death occurred intraoperatively.
Cause of death was pneumonia/acute respiratory dis-
tress syndrome (ARDS) in 8, postpneumonectomy pul-
monary edema/ARDS in 7 patients, ARDS in 4, bron-
chopleural fistula in 4, pulmonary embolus in 4,
myocardial infarction in 3, cardiac arrest in 2, respira-
tory failure in 2, and intraoperative bleeding, stroke,
aspiration, torsion of the left ventricle, and sepsis in 1
patient each. Cause of death was unknown in 6
patients. Seventeen (38.0%) postmortem examinations
were performed. Hospitalization ranged from 4 to 146
days (median 7 days).
Table III. Variables that adversely affected postoper-
ative cardiopulmonary morbidity with univariate
analysis
Significant adverse effect P value
Increased age <.0001
Male sex .04
Respiratory disease .02
Cardiovascular disease <.0001
Smoking (pack-years) .02
Decreased VC (% predicted) .01
Decreased FEV1 (% predicted) <.0001
Decreased FVC (% predicted) .002
Decreased DLCO, exercise (% predicted) .005
Decreased O2 saturation, rest (%) .03
Decreased O2 saturation, exercise (%) .0005
Decreased PaO2 (mm Hg) .007
Preoperative radiation .02
Reinforcement of bronchial stump .007
Parenteral crystalloid, first 24 h .01
Parenteral crystalloid, first 12 h .01
Total units of blood transfusions .02
VC, Vital capacity; FEV1, forced expiratory volume in 1 second; FVC, forced
vital capacity; DLCO, diffusion capacity of the lung to carbon monoxide; O2,
oxygen; PaO2, arterial partial pressure of oxygen.
Table IV. Variables that adversely affected 
postoperative cardiopulmonary morbidity with 
multivariate analysis
Variable P value OR 95% CI
Increased age .0001 1.036 1.02-1.05
Cardiovascular disease .001 1.809 1.27-2.57
Muscle reinforcement 
of bronchial stump .0005 2.086 1.38-3.15
OR, Odds ratio; CI, confidence interval.
Table V. Variables that adversely affected 
postoperative mortality with univariate analysis
Significant adverse effect P value
Cardiovascular disease <.0001
Hematologic disease .005
Preoperative chemotherapy .01
Lower hemoglobin level .004
Decreased DLCO, exercise (% predicted) .002
Right-sided pneumonectomy .0006
Reinforcement of bronchial stump .007
Extended resection .04
Parenteral crystalloid first 12 h .01
DLCO, Diffusion capacity of lung to carbon monoxide.
ity and mortality. Although these data would support
the suggestion of others that excess fluid administra-
tion is both a significant factor in the genesis of respi-
ratory complications22 and an independent predictor of
mortality,14,18 other studies have found no significant
association between fluid administered and the devel-
opment of pulmonary edema.23,24 Because our analysis
was retrospective and uncontrolled, we cannot con-
clude that crystalloid infusion is a contributory factor in
postpneumonectomy respiratory failure. 
Although we did demonstrate that pre-existent hema-
tologic disease and a lower serum hemoglobin level
were associated with increased mortality, we have no
explanation for this observation. Of interest, however,
Harpole and associates16 reported a correlation
between a low hematocrit value and the onset of atrial
arrhythmias after pneumonectomy.
Even if more than half of our patients underwent an
extended or completion pneumonectomy, our mortality
of 7% compares favorably with that reported by others
(3%-12%) (Table VII).8,10-18,25,26 We believe that patient
selection is critical in minimizing complications.1 It is
imperative that the surgeon preoperatively determine
whether a patient can tolerate pneumonectomy. The
presence of cardiovascular disease should be actively
investigated and pre-existent arrhythmias appropriately
managed. Similarly, the respiratory status should be
The Journal of Thoracic and
Cardiovascular Surgery
Volume 121, Number 6
Bernard et al 1079
Cardiopulmonary complications occurred in 245
patients (38.3%; 95% CI 34.6%-42.2%). Factors
adversely affecting morbidity with univariate analysis
are given in Table III. Those adversely affecting mor-
bidity with multivariate analysis are listed in Table IV.
Factors adversely affecting mortality with univariate
analysis are given in Table V and those affecting mor-
tality with multivariate analysis are listed in Table VI.
Factors not affecting morbidity or mortality included
corticosteroid use, chronic renal failure, diabetes melli-
tus, cirrhosis, nonpulmonary malignancy, smoking
within 8 weeks of pneumonectomy, weight loss, stage,
timing of chest tube removal, preoperative total lung
capacity (percent predicted), and residual volume (per-
cent predicted). 
Discussion
Pneumonectomy has the highest complication and
mortality rate of all elective pulmonary resections.1,2
Although our report represents the largest series of con-
secutive pneumonectomies for cancer from a single
institution, comparison with other reports is difficult
because statistical analysis and the number of patients
vary widely.8-18 Nonetheless, many similarities are
noted. As with other series,1 pulmonary and cardiovas-
cular complications were most frequent and accounted
for more than 85% of all complications. For this reason
our morbidity analysis focused mainly on cardiopul-
monary complications. 
Not uncommonly, patients who require pulmonary
resection for lung cancer have pre-existent cardiovas-
cular and/or pulmonary disease. We identified various
factors that adversely affected postoperative morbidity
and mortality. Most of these variables measured airway
obstruction (vital capacity, forced expiratory volume in
1 second, forced vital capacity) and/or impaired gas
exchange (diffusion capacity of the lung to carbon
monoxide, oxygen saturation, PaO2). Like results
reported by others,8,9,19 our data demonstrated that a
decreased diffusion capacity of the lung to carbon mon-
oxide is an independent adverse predictor of postoper-
ative complications.
Pre-existent cardiovascular disease was one of the
strongest predictors of morbidity and mortality. Our
data confirm the reports of others14,16 who demonstrat-
ed that the presence of concomitant cardiovascular dis-
ease was associated with increased mortality. Although
arrhythmias occurred in more than 25% of our patients,
no preoperative risk factors were identified; however,
atrial fibrillation was often coexistent with pneumonia
and respiratory failure.13,20,21
Excess perioperative crystalloid infusion in our
patients had an adverse effect on postoperative morbid-
Table VI. Variables that adversely affected 
postoperative mortality with multivariate analysis
Variable P value OR 95% CI
Hematologic disease .013 5.55 1.44-21.5
Lower hemoglobin level .003 0.78 0.66-0.92
Completion pneumonectomy .01 2.89 1.28-6.53
OR, Odds ratio; CI, confidence interval.
Table VII. Reported pneumonectomy series
First author Year Patients Mortality (%)
Deslauriers10 1989 402* 5
Wahi11 1989 197 7
Romano12 1992 1529† 11.6
Von Knorring13 1992 200 7
Patel14 1992 197 8.6
Miller15 1993 153 5.2
Ferguson8 1995 92 12
Harpole16 1996 136 3
Mizushima17 1997 122 4.1
Swartz18 1997 92 10.9
Mayo 2001 639 7.0
*Series from 2 separate medical centers.
†All non-federal acute care hospitals in the state of California.
evaluated and any reversible condition, such as bron-
chospasm, infection, and smoking, be addressed.
Prevention of complications at the time of operation
is key to reducing perioperative mortality. Hemorrhage
in our series was responsible for one intraoperative
death. Intrapericardial control to prevent intraoperative
hemorrhage may be critical in patients requiring com-
pletion pneumonectomy or having received preopera-
tive hilar radiation.27,28 The bronchial stump also must
be managed with meticulous care, avoiding devascular-
ization and excessive length. Our preference is to rein-
force the bronchial stump with muscle to reduce dehis-
cence if the mediastinum and hilum have been
previously irradiated.29,30 Although our study did
demonstrate that bronchial stump reinforcement was
adversely associated with mortality, we believe that this
is secondary to patient selection because our practice
has been to reinforce the stump in those patients most
likely to have complications. 
We conclude that morbidity and mortality after pneu-
monectomy for malignant disease are multifactorial.
Appropriate selection and meticulous perioperative
care are paramount to minimize risks in those patients
who require pneumonectomy.
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Discussion
Dr Malcolm M. DeCamp, Jr (Cleveland, Ohio).
Pneumonectomy is a disease in and of itself. Because of this,
we as surgeons must be convinced that we are substituting
this disease for a less favorable one. 
Over almost a 13-year experience, these investigators have
performed pneumonectomy in 639 patients. To put this infor-
mation into perspective, it would be important for all of us to
know what the denominator is, what percentage of therapeu-
tic resections for lung cancer during this era were pneu-
monectomies. 
Over 13 years, the mortality for pneumonectomy in this insti-
tution was 7%. This is certainly within range of others’ pub-
lished experiences. The results, however, are even more impres-
sive if we consider that 23% of the pneumonectomies were for
T3 or T4 lesions and necessitated resection of associated chest
wall, left atrium, carina, diaphragm, superior vena cava,
esophageal wall, or aortic wall. I would be interested in a break-
down of the mortality figures for this higher risk group. 
Dr Deschamps, 343 of your patients had locally advanced
disease as reflected by postoperative resected stages IIIA or
IIIB. Despite this, only 285 patients underwent medi-
astinoscopy. What is your institutional approach to central
lesions that are likely to require pneumonectomy? 
Despite the fact that more than half of the group had stage
IIIA or IIIB disease, only 63, or roughly 18%, of this high-
risk patient group had some form of induction therapy. There
is now fairly compelling evidence that multimodal therapy
offers a survival advantage for such patients. Has the philos-
ophy of therapy for stage III disease evolved over this same
era at the Mayo Clinic? 
Perhaps one of the most feared complications and conse-
quences of pneumonectomy is postpneumonectomy empye-
ma and bronchopleural fistula. Postpneumonectomy empye-
ma developed in 5.6% of your patients, associated with a
bronchopleural fistula in two thirds of these patients. Four of
the 25 patients with a bronchopleural fistula died. Muscle
reinforcement of your bronchial stump was found to be an
independent predictor of postoperative morbidity. How many
of these patients had empyema or postoperative bron-
chopleural fistula despite aggressive therapy for their
bronchial stump in the operating room? 
Finally, the stated objective of this work was to assess for
factors affecting morbidity and mortality after pneumonecto-
my. To do this, you have performed a very exhaustive uni-
variable and multivariable analysis looking at a host of fac-
tors, and you have defined 3 independent variables that pre-
dict morbidity and 3 separate independent variables that pre-
dict mortality. 
I would have to direct you to some similar prospective
work that Harpole and I did in conjunction with the Veterans
Affairs Cooperative Group, published in 1999 (J Thorac
Cardiovasc Surg 1999;117:969-79), in which we looked at
567 pneumonectomies performed between 1991 and 1995.
We also found, in a multivariable analysis, 8 distinct preop-
erative factors predictive for 30-day mortality and a separate
8 distinct variables predictive for 30-day morbidity. The goal
of our study was to create a prognostic model to allow prac-
titioners to assess risk and counsel patients accordingly. 
How would you propose to use the specific data that you
have gleaned from your work to better select patients for
pneumonectomy? For example, as advanced age was a pre-
dictor of morbidity in your series, is there a particular cutoff
above which you might not recommend surgery? Similarly,
preoperative anemia was predictive of postoperative mortali-
ty in your experience. Would preoperative transfusion
enhance the survivability of these patients? 
Dr Deschamps. Thank you very much, Dr DeCamp, for
your kind review. 
Pneumonectomy in our institution constitutes about 15% of
all pulmonary resections for cure. We have not broken down
our morbidity by stage. 
As you probably know, mediastinoscopy has not been used
routinely in our institution. As we have increasingly become a
part of the community that does protocols, we have seen our-
selves doing mediastinoscopy more frequently in the past 10
years. Right now we do use mediastinoscopy in patients who
are not on protocol if they have abnormal lymph nodes on
computed tomographic scan or disease that is likely to need a
pneumonectomy. We also use mediastinoscopy in patients
whose condition is compromised and whom we think will not
tolerate a radical resection such as a pneumonectomy. 
The role of preoperative treatment has evolved in our insti-
tution, too. Like other institutions, we are embarking on more
and more protocols for preoperative treatment. At this point,
we do think that preoperative treatment has its role in patients
with N2 disease. 
We are still trying to examine the data, but we have not
been successful in preventing all bronchopleural fistulas by
using prophylactic muscle flaps. We do not reinforce the
bronchial stump in a randomized fashion, so it is not cer-
tain that using a muscle will have a significant effect in pre-
venting bronchopleural fistula. Many of our patients are
considered at risk for bronchopleural fistula. Pairolero
started using prophylactic muscle a long time ago and still
favors it. Our group concurs, of course, that the patient who
has had radiation, chemotherapy, or a significant pleural
space infection might benefit from reinforcement with a
muscle, but we have seen failures and we are still evaluat-
ing the data. 
Finally, I do not know how I would propose using a cutoff,
since using a cutoff for every or any variable is a subjective
and arbitrary decision. Who am I to say that a patient who is
69 years old should not have a pneumonectomy only because
in our study increased age has been a factor? Actually, our
mortality is not significantly higher between the group
younger than 70 years and the group older than 70 years.
Mortality is, of course, higher, but it is not significantly high-
er. We do not know yet whether a hemoglobin value of 12
g/dL is better than 9 g/dL or whether an age of 70 years is bet-
ter than 75 years or a PO2 of 65 mm Hg is better than 59 mm
Hg? We are not going to try to establish cutoff criteria. We do
not have survival criteria, but certainly mediastinoscopy is an
operation that is needed in many patients. 
Bronchoplastic surgery is not applicable to all patients.
Pneumonectomy is an operation that thoracic surgeons
should not fear but rather should do with confidence when it
is needed. 
Dr Carolyn E. Reed (Charleston, SC). The number of
patients and the consistency in this report add significantly to
the literature. Many of the findings are not surprising, but
some of them are intriguing. I was intrigued by the finding
that the hemoglobin level was an important factor for postop-
erative mortality. It is certainly something that we can do
something about ahead of time. Knowing your data now,
would you do something about it?
I was also dismayed that 47% of your patients had stage
IIIA disease. We certainly would avoid doing a pneumonec-
tomy in that group at our institution, if possible, and would do
a very thorough metastatic survey. What was your standard
for metastatic survey? Also, what was the overall survival in
this particular group of patients who underwent pneumonec-
tomy? 
Multivariate analysis showed that bronchial stump rein-
forcement affected morbidity. Could you break that down?
We know that patients with right pneumonectomies after
chemotherapy/radiation are a particularly high-risk group.
What was the result in this subset of patients in your hands? 
Dr Deschamps. Dr Reed, thank you for your comments. 
A patient who comes to a pneumonectomy with a hemo-
globin of 8 g/dL will receive a transfusion before the opera-
tion, and I will not feel too uncomfortable. Given our data, I
would prefer to do the transfusion before the operation, on an
outpatient basis, rather than during the operation. 
At the present time at the Mayo Clinic we do not do a
workup for metastatic disease unless there are abnormal
physical findings, abnormal subjective findings, and abnor-
mal laboratory findings, such as elevated hepatic enzymes,
and unless there are findings on the computed tomographic
scan. Every patient will have a physical examination, regular
blood tests, bone enzyme studies, and liver enzyme studies,
and the computed tomographic scan will cover the upper part
of the abdomen and the chest. With this regimen, we think
that we adequately evaluate most patients. Of course, we
might be wrong and time will tell. We do not have survival
data. 
For the purpose of this study, we did not break down the
survival by stage and by chemoradiation therapy.
Dr Denise Ouellette (Montreal, Quebec, Canada). I have
2 questions: First, what was the mortality rate of the patients
having right pneumonectomies? Second, what type of lesion
did the patients with stage IA disease have to require a pneu-
monectomy? 
Dr Deschamps. Our mortality was higher for right pneu-
monectomy, but not by much—about 9% versus 6%.
I do not have the breakdown on stage of disease, but the high-
er the stage, the more complications and the more mortalities.
However, the difference was not statistically significant. 
Dr John R. Benfield (Los Angeles, Calif). This is a won-
derful paper to illustrate that statistical analysis at times does
not really help to interpret results. It reminds me of the story
about the Philadelphia medical examiner in the early days of
intravenous fluid therapy, saying that such treatment is bad
because all the patients that he was examining post mortem
had been given intravenous fluids. My point is that it is erro-
neous to refer to the use of muscle flaps to protect the
bronchial stump as a “mortality factor.” We use muscle flaps
when the patient is at higher-than-usual risk for bron-
chopleural fistula. Thus, the interesting facts we have heard
are less meaningful than stated, and they must not be inter-
preted as evidence to suggest that muscle flaps should not be
used to cover bronchial stumps after pneumonectomies.
I wanted to ask you about the long-term outcome after
pneumonectomies for stage III cancers in the hope that you
would say they are now even better than they were in an
article in The Journal of Thoracic and Cardiovascular
Surgery by Peter Pairolero from your institution perhaps 9
or more years ago. I believe the long-term survival after
resections of stage III cancers was about 26% without
induction therapy. You already said that you do not have the
information about which I was going to ask, and so I sim-
ply call attention to the fact that those results without
induction therapy are about the same as the current best
results after induction therapy.
Dr Deschamps. Dr Benfield, thank you for your comments. 
I am still waiting to be praised for our 97% lymphadenec-
tomy rate. Now that I have said that, we decided to look at the
muscle data and did find that it was a factor of morbidity. Of
course, patients treated with muscle flaps were sick patients,
and we covered that topic in the discussion section. The data
were there, and we had to find an explanation. Statistics do
have their limits, but we still favor doing muscle flaps in all
patients whom we think are at risk of having a fistula. A
prospective study would be useful.
Dr Robert L. Thurer (Boston, Mass). As the
Association’s representative to the American Association of
Blood Banks, I feel compelled to make some comments
about anemia. Although it may be true that anemia is a mark-
er for worse outcome and correction of anemia is valuable in
patients having pneumonectomy, it is quite another thing to
say that correcting the anemia will eliminate that as a marker
for a bad outcome. Anemia may represent a poor physiolog-
ic status related to tumor size, occult metastatic disease, or
other factors that may affect outcome. We should not leap to
the conclusion that correction of anemia will eliminate pre-
operative anemia as an adverse factor.
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